---
id: idsa-fungal-2024
title: "IDSA Clinical Practice Guideline for Management of Invasive Fungal Infections"
short_title: "Invasive Fungal Infections"
organization: Infectious Diseases Society of America
country: United States
url: https://www.idsociety.org/practice-guideline/invasive-fungal-infections/
specialty: infectious-disease
guideline_type: clinical-practice
evidence_system: idsa-grade
conditions:
  - Invasive Aspergillosis
  - Invasive Candidiasis
  - Cryptococcosis
  - Mucormycosis
tags:
  - invasive fungal infection
  - aspergillosis
  - candidiasis
  - antifungal therapy
publication_date: 2024-05-01
previous_version_date: 2016-06-29
status: current
supersedes: idsa-aspergillosis-2016
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides recommendations for the diagnosis, prevention, and treatment of invasive fungal infections, including aspergillosis, candidiasis, cryptococcosis, and mucormycosis.

## Key Recommendations

### Invasive Aspergillosis
**Diagnosis:**
- Galactomannan (serum and BAL)
- Beta-D-glucan
- CT imaging (halo sign, air crescent)
- Culture and histopathology

**Treatment:**
- Voriconazole (first-line)
- Isavuconazole (alternative first-line)
- Liposomal amphotericin B for azole-intolerant
- Posaconazole for prophylaxis in high-risk

**Duration:**
- Minimum 6-12 weeks
- Continue until immunosuppression resolved
- Surgical resection for focal disease when feasible

### Invasive Candidiasis
**Empiric Therapy (Candidemia):**
- Echinocandin first-line (micafungin, caspofungin, anidulafungin)
- Fluconazole for stable, non-critical patients if susceptible

**Duration:**
- 14 days from first negative blood culture
- Longer for deep-seated infection (endocarditis, meningitis)

**Central Line:**
- Remove CVC if feasible

### Cryptococcosis
**CNS Disease:**
- Induction: Liposomal amphotericin B + flucytosine x 2 weeks
- Consolidation: Fluconazole 400-800mg x 8 weeks
- Maintenance: Fluconazole 200mg until immune reconstitution

**Pulmonary (Non-CNS):**
- Mild-moderate: Fluconazole 400mg x 6-12 months
- Severe: Treat as CNS disease

### Mucormycosis
- Liposomal amphotericin B (high dose)
- Isavuconazole alternative
- Aggressive surgical debridement essential
- Control underlying risk factors (DKA, immunosuppression)
